Model-Based Analysis of Impact, Costs, and Cost-effectiveness of Tuberculosis Outbreak Investigations, United States

被引:0
|
作者
Shrestha, Sourya [1 ]
Cilloni, Lucia [1 ]
Asay, Garrett R. Beeler [2 ]
Kammerer, J. Steve [2 ]
Raz, Kala [2 ]
Shaw, Tambi [3 ]
Cilnis, Martin [3 ]
Wortham, Jonathan [2 ]
Marks, Suzanne M. [2 ]
Dowdy, David [1 ]
机构
[1] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA
[2] CDCP, Atlanta, GA USA
[3] Calif Dept Publ Hlth, Richmond, CA USA
关键词
MYCOBACTERIUM-TUBERCULOSIS; LATENT; INFECTION; TRANSMISSION; INDIVIDUALS; RIFAPENTINE; REGIMEN; DISEASE;
D O I
10.3201/eid3103.240633
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Outbreak investigation is an essential component of tuberculosis (TB) control in the United States, but its epidemiologic impact and cost-effectiveness have not been quantified. We modeled outbreak investigation activities in the United States during 2023-2032 and estimated corresponding epidemiologic impact, economic costs (in 2022 US$), and incremental cost-effectiveness ratios from the healthcare system perspective (cost per additional quality-adjusted life-year gained). We projected that outbreak investigations would result in 1,030,000 (95% uncertainty interval [UI] 376,000- 1,740,000) contacts investigated, leading to 4,130 (95% UI 1,420-7,640) TB diagnoses and 104,000 (95% UI 37,600-181,000) latent TB infection diagnoses, at a total cost of US $219 million (95% UI $80-$387 million). We estimated that 5,560 (95% UI 1,720-11,400) TB cases would be averted through early detection and treatment, and the incremental cost-effectiveness of outbreak investigations, compared with no outbreak investigations, was $27,800 per quality-adjusted life-year gained (95% UI $4,580-$68,700).
引用
收藏
页码:497 / 506
页数:10
相关论文
共 50 条
  • [1] Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis
    G. B. Gomez
    D. W. Dowdy
    M. L. Bastos
    A. Zwerling
    S. Sweeney
    N. Foster
    A. Trajman
    M. A. Islam
    S. Kapiga
    E. Sinanovic
    G. M. Knight
    R. G. White
    W. A. Wells
    F. G. Cobelens
    A. Vassall
    BMC Infectious Diseases, 16
  • [2] Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis
    Gomez, G. B.
    Dowdy, D. W.
    Bastos, M. L.
    Zwerling, A.
    Sweeney, S.
    Foster, N.
    Trajman, A.
    Islam, M. A.
    Kapiga, S.
    Sinanovic, E.
    Knight, G. M.
    White, R. G.
    Wells, W. A.
    Cobelens, F. G.
    Vassall, A.
    BMC INFECTIOUS DISEASES, 2016, 16
  • [3] Cost-Effectiveness Analysis of BCG Vaccination against Tuberculosis in Indonesia: A Model-Based Study
    Machlaurin, Afifah
    Dolk, Franklin Christiaan Karel
    Setiawan, Didik
    van der Werf, Tjipke Sytse
    Postma, Maarten J.
    VACCINES, 2020, 8 (04) : 1 - 14
  • [4] The cost-effectiveness of meniscal repair versus partial meniscectomy: A model-based projection for the United States
    Feeley, Brian T.
    Liu, Shan
    Garner, Abigail M.
    Zhang, Alan L.
    Pietzsch, Jan B.
    KNEE, 2016, 23 (04): : 674 - 680
  • [5] Cost-effectiveness Analysis and Geographic Variation in Health Care Costs in the United States
    Predmore, Zachary
    MEDICAL DECISION MAKING, 2019, 39 (01) : 3 - 4
  • [6] THE COST-EFFECTIVENESS OF MENISCAL REPAIR VERSUS PARTIAL MENISCECTOMY: A MODEL-BASED PROJECTION OF CLINICAL OUTCOMES AND COSTS IN THE UNITED STATES HEALTHCARE SYSTEM
    Feeley, B.
    Liu, S.
    Garner, A. M.
    Zhang, A.
    Pietzsch, J. B.
    VALUE IN HEALTH, 2015, 18 (03) : A158 - A158
  • [7] Estimation of the cost-effectiveness of HIV prevention portfolios for people who inject drugs in the United States: A model-based analysis
    Bernard, Cora L.
    Owens, Douglas K.
    Goldhaber-Fiebert, Jeremy D.
    Brandeau, Margaret L.
    PLOS MEDICINE, 2017, 14 (05)
  • [8] Cost-effectiveness analysis in the United States - Reply
    Pearson, SD
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (23): : 2722 - 2723
  • [9] Impact and cost-effectiveness of strategies to accelerate cervical cancer elimination: A model-based analysis
    Portnoy, Allison
    Pedersen, Kine
    Trogstad, Lill
    Hansen, Bo T.
    Feiring, Berit
    Laake, Ida
    Smith, Megan A.
    Sy, Stephen
    Nygard, Mari
    Kim, Jane J.
    Burger, Emily A.
    PREVENTIVE MEDICINE, 2021, 144
  • [10] Disparities in model-based cost-effectiveness analyses of tuberculosis diagnosis: A systematic review
    Padmasawitri, T. I. Armina
    Frederix, Gerardus W.
    Alisjahbana, Bachti
    Klungel, Olaf
    Hovels, Anke M.
    PLOS ONE, 2018, 13 (05):